Pantec Biosolutions specializes in laser microporation technology to enable transdermal delivery of large molecular weight biopharmaceuticals into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform is designed to provide needle-free, painless administration and individualized dosages via partnered patch technology. The company intends to use recent funding to drive development, regulatory approval and the market launch of the P.L.E.A.S.E.® platform. Pantec is based in Ruggell, Liechtenstein. The firm announced a CHF 20m investment from StemCell Holding to support these objectives. The capital and board changes are positioned to accelerate commercialization activities.

Total raised

$19M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2010